Table 8 Top 15 Differentially Variable Regions for lymphatic–hematopoietic cancers
Positions | Chr | Width | N CpGs | Stouffer p value | Gene | Function | Overlapping promoters |
|---|---|---|---|---|---|---|---|
24910562: 24912896 | chr6 | 2335 | 21 | 1.55E−51 | FAM65B | Inhibits the proliferation of human leukemic T cells | FAM65B-001 |
32447944: 32456069 | chr11 | 8126 | 42 | 7.89E−33 | WT1 | Oncogene in Acute Myeloid Leukemia | WT1-001, WT1-005, WT1-002, WT1-AS-001, WT1-AS-201, WT1-AS-005, WT1-009, WT1-004, WT1-AS-003, WT1-AS-004, WT1-AS-002, WT1-AS-006, WT1-006, WT1-003 |
748992: 749620 | chr20 | 629 | 9 | 1.66E−23 | SLC52A3 | Predictive and prognostic biomarker in esophageal cancer | SLC52A3-001, SLC52A3-004, SLC52A3-003 |
36147197: 36150135 | chr20 | 2939 | 48 | 1.08E−17 | BLCAP | Regulates cell proliferation and coordinate apoptosis and cell cycle progression. Associated to bladder and cervical cancers | NNAT-001, NNAT-002, BLCAP-009, BLCAP-010, BLCAP-005 |
27141388: 27144595 | chr7 | 3208 | 28 | 2.55E−17 | HOXA2 | Aberrant expression associated to several cancers | HOXA2-001 |
16829666: 16830859 | chr19 | 1194 | 10 | 8.58E−12 | NWD1 | Suggested causal role in dysregulation of androgen receptor signaling during prostate cancer progression | NWD1-002, NWD1-001, NWD1-006 |
42950995: 42952369 | chr5 | 1375 | 5 | 6.85E−11 | LOC648987 | Uncharacterized function | - |
157164556:157165335 | chr1 | 780 | 5 | 1.72E−10 | ETV3 | Transcriptional repressor associated to dendritic cell tumor | - |
13120555: 13123217 | chr19 | 2663 | 7 | 3.50E−10 | NFIX | DNA-binding transcription factor activity | NFIX-009, NFIX-008 |
121624862: 121625735 | chr2 | 874 | 6 | 2.07E−09 | GLI2 | Zinc finger protein thought to play a role in embryogenesis | RP11-297J22.1-001 |
36665826: 36667782 | chr17 | 1957 | 10 | 2.23E−09 | ARHGAP23 | Increases p53 proto-oncogene’s transactivity | - |
46997630: 46999840 | chr19 | 2211 | 19 | 1.03E−08 | PPP5D1 | MAPK signaling pathway. Abnormal MAPK signaling may lead to uncontrolled cell proliferation and resistance to apoptosis | AC011484.1-201, PNMAL2-201, PNMAL2-004, PNMAL2-001 |
42431109: 42433041 | chr17 | 1933 | 8 | 1.68E−08 | FAM171A2 | Associated to ceroid lipofuscinosis | GRN-022 |
78526804: 78527410 | chr15 | 607 | 5 | 3.19E−08 | ACSBG1 | Associated to malignant ovarian surface epithelial-stromal neoplasm and ovary epithelial cancer | ACSBG1-001, ACSBG1-201, ACSBG1-012, ACSBG1-014, ACSBG1-002, ACSBG1-008, ACSBG1-003 |
17603531: 17604184 | chr17 | 654 | 6 | 3.55E−08 | RAI1 | Transcriptional regulator of the circadian clock components. Chromatin remodeling | - |